These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24833067)

  • 1. Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.
    Huang B; Giannini EH; Lovell DJ; Ding L; Liu Y; Hashkes PJ
    Contemp Clin Trials; 2014 Jul; 38(2):204-12. PubMed ID: 24833067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF.
    Hashkes PJ; Huang B
    Isr Med Assoc J; 2015 Mar; 17(3):137-40. PubMed ID: 25946762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.
    Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ
    BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma.
    Hirakawa A; Nishikawa T; Yonemori K; Shibata T; Nakamura K; Ando M; Ueda T; Ozaki T; Tamura K; Kawai A; Fujiwara Y
    Ther Innov Regul Sci; 2018 May; 52(3):334-338. PubMed ID: 29714533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials.
    Bajard A; Chabaud S; Cornu C; Castellan AC; Malik S; Kurbatova P; Volpert V; Eymard N; Kassai B; Nony P;
    J Clin Epidemiol; 2016 Jan; 69():125-36. PubMed ID: 26186899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases.
    Sebastien B
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):495-499. PubMed ID: 37148459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.
    Hashkes PJ; Spalding SJ; Hajj-Ali R; Giannini EH; Johnson A; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright D; Lovell DJ; Huang B
    Biomed Res Int; 2014; 2014():854842. PubMed ID: 25147819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation study for evaluating the performance of response-adaptive randomization.
    Du Y; Wang X; Jack Lee J
    Contemp Clin Trials; 2015 Jan; 40():15-25. PubMed ID: 25460340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
    Portincasa P; Scaccianoce G; Palasciano G
    Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A three-stage clinical trial design for rare disorders.
    Honkanen VE; Siegel AF; Szalai JP; Berger V; Feldman BM; Siegel JN
    Stat Med; 2001 Oct; 20(20):3009-21. PubMed ID: 11590629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.
    Bayar MA; Le Teuff G; Michiels S; Sargent DJ; Le Deley MC
    Stat Med; 2016 Aug; 35(19):3245-58. PubMed ID: 27027783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for adaptive crossover trial in detecting gene-drug interactions.
    Chen HY; Darbar D
    Stat Methods Med Res; 2023 Sep; 32(9):1680-1693. PubMed ID: 37431594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triggers for attacks in familial Mediterranean fever: application of the case-crossover design.
    Yenokyan G; Armenian HK
    Am J Epidemiol; 2012 May; 175(10):1054-61. PubMed ID: 22234484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.
    Wei B; Braun TM; Tamura RN; Kidwell K
    J Biopharm Stat; 2020 Nov; 30(6):1109-1120. PubMed ID: 32892710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.
    Smania G; Baiardi P; Ceci A; Magni P; Cella M
    CPT Pharmacometrics Syst Pharmacol; 2016 Jun; 5(6):305-12. PubMed ID: 27300083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.